/ Print /

Policy & Regulation Strategy

Three Orphan Drug Program problems and how the FDA plans to fix themRecently, FDA Commissioner Scott Gottlieb announced the FDA will move to close loopholes in the Orphan Drug Program. Here’s what you need to know.
Two opioid use disorder drug developments to watchNew physician-administered therapies on the horizon may help rein in the opioid epidemic.
Population health prevails despite ACA uncertainties, other barriersA survey of nearly 200 healthcare executives has interesting findings related to population health management.
CMS quality payment program year 2 proposal: 8 things to knowCMS’ Quality Payment Program launched in 2016 as part of MACRA. Here’s what’s in store for Year 2.
Opinion: Cost transparency improves collections and boosts satisfactionConsider providing cost estimates prior to rendering care to increase collections, patient satisfaction.
How Americans really feel about the AHCAA new Kaiser poll has surprising results and three important findings.
AHCA next steps: 4 things MCOs should knowWhat are the next steps for the bill, and how likely is it that it will become law? Here’s are four things MCOs should know.
Opinion: Biggest problems with single-payer ‘Medicare-for-all’Our policy analyst explains why he believes single payer Medicare-for-all is a pipe dream.
Top ACA provisions employers want to keepA Willis Towers Watson survey finds that employers see enhancing the employee experience in healthcare as key to boosting health engagement.
Congress considering ‘invisible’ high-risk poolsOur policy analyst explains the concept of invisible high-risk pools, and explains how they might affect health reform.